US 12,227,562 B2
Compositions and methods to treat viral infection and co-morbidities
Yury Miller, San Diego, CA (US); Michael Bukrinsky, Washington D.C., DC (US); and Dmitri Sviridov, Melbourne (AU)
Assigned to The Regents of the University of California, Oakland, CA (US); The George Washington University, Washington D.C., DC (US); and Baker Heart and Diabetes Research Institute., Melbourne (AU)
Filed by The Regents of the University of California, Oakland, CA (US); The George Washington University, Washington D.C., DC (US); and Baker Heart and Diabetes Research Institute, Melbourne (AU)
Filed on Dec. 7, 2021, as Appl. No. 17/544,416.
Claims priority of provisional application 63/122,203, filed on Dec. 7, 2020.
Prior Publication US 2022/0177559 A1, Jun. 9, 2022
Int. Cl. C07K 16/18 (2006.01); A61P 31/18 (2006.01); B82Y 5/00 (2011.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 31/18 (2018.01); A61K 2039/505 (2013.01); B82Y 5/00 (2013.01)] 16 Claims
 
1. A method for inhibiting, or slowing the rate of human immunodeficiency virus (HIV) replication in vivo,
the method comprising:
(a) providing or having provided a recombinant protein having Apolipoprotein A-I binding protein (AIBP) activity or a composition comprising the recombinant protein having Apolipoprotein A-I binding protein (AIBP) activity,
wherein the recombinant protein is encoded by a nucleic acid comprising a sequence as set forth in SEQ ID NO:10, and
(b) administering to an individual in need thereof the recombinant protein or the composition.